Drug prices are the key to easing the PAH benefit standard
By Choi-sun | translator Choi HeeYoung
21.09.16 11:37:23
°¡³ª´Ù¶ó
0
the debate on establishing measures to improve the survival rate of PAH (pulmonary arterial hypertension)
reparing amendments such as indicators standards" Announcement of negotiations between the MOHW and pharmaceutical companies
The opinions were fully reflected
There is a possibility that PAH tx benefit standard, which has been criticized by strict standards, will be eased. As the HIRA mentioned that it has prepared an amendment that fully reflects the opinions of the society on the application indicators of combination therapy and the initial three-drug combination pointed out as a problem, the public has passed over to the MOHW.
On the 15th, the Korean guideline for diagnosis and treatment of treatment and the Korean Pulmonary Hypertension Association held a National Assembly debate with Heo Jong-sik, a member of the National Assembly's Health and Welfare Committee, to establish measures to improve the survival rate of patients with PAH.
In Korea
Choi-sun(news@medicaltimes.com)
If you want to see the full article, please JOIN US (click)